Clinical Trials Sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Total 57 results

Shanghai Yidian Pharmaceutical Technology Development...

Recruiting

HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer

Recurrent Extensive Stage Small Cell Lung Carcinoma

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

Healthy Participants
Shanghai Medinno Pharmaceutical Technology Co.,...

Recruiting

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults

Allergic Conjunctivitis

Australia
Shanghai Yinnuo Pharmaceutical Technology Co.,...

Active, not recruiting

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment

Type2 Diabetes

China
Shanghai Yinnuo Pharmaceutical Technology Co.,...

Active, not recruiting

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients

Type2 Diabetes

China
Shanghai Haiyan Pharmaceutical Technology Co.,...

Recruiting

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Solid Tumor

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Haiyan Pharmaceutical Technology Co.,...

Recruiting

Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Insomnia Disorder

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Recruiting

A Phase I Trial of Simmitinib in Advanced Solid Tumors

Advanced Solid Tumor

China
Overseas Pharmaceuticals, Ltd.
Beijing Capton Pharmaceutical Technology Development Co., LTD

Not yet recruiting

An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.

Epilepsy

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Advanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall Cell

China
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.

Breast Cancer | Solid Tumor

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Langerhans Cell Histiocytosis | LCH

China
Shanghai Fosun Pharmaceutical Industrial Development...

Suspended

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Melanoma

China
Shanghai Fosun Pharmaceutical Industrial Development...

Terminated

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Advanced Cancer | Solid Tumors | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States, Australia
Shanghai Yinnuo Pharmaceutical Technology Co.,...
Huashan Hospital

Not yet recruiting

Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

Healthy Volunteers
Shanghai Yiteng Jingang Bio-pharmaceutical Technology...

Recruiting

A Study of EOC237 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Not yet recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Active, not recruiting

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Ovarian Cancer

China
Shanghai Yinnuo Pharmaceutical Technology Co.,...
Shanghai 6th People's Hospital

Completed

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

China
Shanghai Jiaolian Drug Research and Development...
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Shanghai Jiaolian Drug Research and Development...
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere Zaiming

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumor

United States, China
Shanghai Henlius Biotech
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; HeNan Sincere...

Recruiting

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

SARS-CoV-2 Infection

Malaysia, Philippines
BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Completed

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

SARS-CoV-2

China
BioNTech SE
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Completed

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

SARS-CoV-2

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Jilin Provincial Tumor Hospital

Recruiting

A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors

Locally Advanced Unresectable Carcinoma

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Osteosarcoma
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Hypercalcemia of Malignancy
Shanghai Henlius Biotech
Huashan Hospital; Shanghai Fosun Pharmaceutical Industrial Development Co....

Not yet recruiting

Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

COVID-19
Kexing Biopharm Co., Ltd.
The Third Hospital of Changsha; Guoxin Pharmaceutical Technology (Beijing)... and other collaborators

Completed

A Phase I Study in Healthy Participants

Healthy Participants

China
Shanghai Henlius Biotech
Huashan Hospital; Shanghai Fosun Pharmaceutical Industrial Development Co.... and other collaborators

Recruiting

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Ousehold in China

COVID-19

China
First Affiliated Hospital of Harbin Medical University
Shanghai baiying pharmaceutical technology Co., Ltd.

Unknown

Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis (EIAIETNKOA)

Osteoarthritis of Knee

China
Women's Hospital School Of Medicine Zhejiang University
ORGANON (SHANGHAI) PHARMACEUTICAL TECHNOLOGY CO., LTD.

Not yet recruiting

Comparison of Clinical Outcomes in Fresh Cycle With Single Blastocyst Stage and Double Cleavage-stage Embryos: a Single-center, Non-blind, Randomized Controlled Study

Infertility, Female
Shanghai Jiao Tong University School of Medicine
Shanghai Chest Hospital; Shanghai Municipal Science and Technology Commission; Simcere Pharmaceutical Co., Ltd

Completed

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) (Dengshan)

Non-small Cell Lung Cancer

China
Edwards Lifesciences
Rundo International Pharmaceutical Research & Development Co.,Ltd.; Edwards... and other collaborators

Active, not recruiting

INSPIRIS China PMCF Study (INSPIRIS China)

Aortic Valve Replacement

China
Dongzhimen Hospital, Beijing
Beijing Union pharmaceutical factory II; Beijing Compete Medical Technology...

Completed

Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia

Vascular Dementia

China
Shanghai Yinnuo Pharmaceutical Technology Co.,...
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...

Completed

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

Diabetes Mellitus, Type 2

China
Peking University People's Hospital
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.; Beijing CSCO-Allist... and other collaborators

Not yet recruiting

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Adenocarcinoma of Lung

China
University of Oxford
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; National Institute... and other collaborators

Completed

Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate (1STEP-AS)

Severe Malaria

Congo, The Democratic Republic of the
Wan-Guang Zhang
BeiGene; Geneplus-Beijing Co. Ltd.; Simcere Pharmaceutical Co., Ltd; Chinese Cooperative... and other collaborators

Recruiting

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC (CCGLC-007)

Hepatocellular Carcinoma

China

Clinical Trials Sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations